MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
MicroRNAs (miRNAs) are small, noncoding RNAs that regulate expression of many genes. Recent studies suggest roles of miRNAs in carcinogenesis. We and others have shown that expression profiles of miRNAs are different in lung cancer vs. normal lung, although the significance of this aberrant expression is poorly understood. Among the reported down-regulated miRNAs in lung cancer, the miRNA (miR)-29 family (29a, 29b, and 29c) has intriguing complementarities to the 3′-UTRs of DNA methyltransferase (DNMT)3A and -3B ( de novo methyltransferases), two key enzymes involved in DNA methylation, that are frequently up-regulated in lung cancer and associated with poor prognosis. We investigated whether miR-29s could target DNMT3A and -B and whether restoration of miR-29s could normalize aberrant patterns of methylation in non-small-cell lung cancer. Here we show that expression of miR-29s is inversely correlated to DNMT3A and -3B in lung cancer tissues, and that miR-29s directly target both DNMT3A and -3B. The enforced expression of miR-29s in lung cancer cell lines restores normal patterns of DNA methylation, induces reexpression of methylation-silenced tumor suppressor genes, such as FHIT and WWOX, and inhibits tumorigenicity in vitro and in vivo . These findings support a role of miR-29s in epigenetic normalization of NSCLC, providing a rationale for the development of miRNA-based strategies for the treatment of lung cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bartel (2004) · doi:10.1016/s0092-8674(04)00045-5 · Cited by 34,714
MicroRNA signatures in human cancers
Calin, G. A., & Croce, C. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1997 · Cited by 7,590
Self-citationJemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., & Thun, M. J. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.1.43 · Cited by 7,439
Okano, M., Bell, D. W., Haber, D. A., & Li, E. (1999) · Cell · doi:10.1016/s0092-8674(00)81656-6 · Cited by 6,143
Oncomirs—MicroRNAs with a role in cancer
Esquela-Kerscher, A., & Slack, F. J. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1840 · Cited by 5,884
A microRNA expression signature of human solid tumors defines cancer gene targets
Volinia, S., Calin, G. A., Liu, C.-G., Ambs, S., Cimmino, A., Petrocca, F., Visone, R., Iorio, M., Roldo, C., Ferracin, M., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510565103 · Cited by 5,697
Self-citationPrediction of Mammalian MicroRNA Targets
Lewis, B. P., Shih, I.-H., Jones-Rhoades, M. W., Bartel, D. P., & Burge, C. B. (2003) · Cell · doi:10.1016/s0092-8674(03)01018-3 · Cited by 5,199
Real-time quantification of microRNAs by stem-loop RT-PCR
Chen, C. (2005) · Nucleic Acids Research · doi:10.1093/nar/gni178 · Cited by 4,952
Combinatorial microRNA target predictions
Krek, A., Grün, D., Poy, M. N., Wolf, R., Rosenberg, L., Epstein, E. J., MacMenamin, P., da Piedade, I., Gunsalus, K. C., Stoffel, M., et al. (2005) · Nature Genetics · doi:10.1038/ng1536 · Cited by 4,603
Jones, P. A., & Baylin, S. B. (2007) · Cell · doi:10.1016/j.cell.2007.01.029 · Cited by 4,515
Cited by
Items 101–150 of 150
A Systematic Review of miR-29 in Cancer
Kwon, J. J., Factora, T. D., Dey, S., & Kota, J. (2019) · Molecular Therapy Oncolytics · doi:10.1016/j.omto.2018.12.011 · Cited by 263
Roles of small RNAs in tumor formation
Di Leva, G., & Croce, C. M. (2010) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.04.001 · Cited by 262
Self-citationGAMBARI, R., BROGNARA, E., SPANDIDOS, D. A., & FABBRI, E. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3503 · Cited by 262
Taulli, R., Bersani, F., Foglizzo, V., Linari, A., Vigna, E., Ladanyi, M., Tuschl, T., & Ponzetto, C. (2009) · Journal of Clinical Investigation · doi:10.1172/jci38075 · Cited by 260
Epigenetic targets of bioactive dietary components for cancer prevention and therapy
Meeran, S. M., Ahmed, A., & Tollefsbol, T. O. (2010) · Clinical Epigenetics · doi:10.1007/s13148-010-0011-5 · Cited by 255
MicroRNA-199b-5p Impairs Cancer Stem Cells through Negative Regulation of HES1 in Medulloblastoma
Garzia, L., Andolfo, I., Cusanelli, E., Marino, N., Petrosino, G., De Martino, D., Esposito, V., Galeone, A., Navas, L., Esposito, S., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004998 · Cited by 255
Wong, C. C.-L., Tse, A. P.-W., Huang, Y.-P., Zhu, Y.-T., Chiu, D. K.-C., Lai, R. K.-H., Au, S. L.-K., Kai, A. K.-L., Lee, J. M.-F., Wei, L. L., et al. (2014) · Hepatology · doi:10.1002/hep.27320 · Cited by 253
Shioya, M., Obayashi, S., Tabunoki, H., Arima, K., Saito, Y., Ishida, T., & Satoh, J. (2010) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2010.01076.x · Cited by 245
Lv, M., Zhong, Z., Huang, M., Tian, Q., Jiang, R., & Chen, J. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2017.08.001 · Cited by 222
Biology of premature ageing in survivors of cancer
Cupit-Link, M. C., Kirkland, J. L., Ness, K. K., Armstrong, G. T., Tchkonia, T., LeBrasseur, N. K., Armenian, S. H., Ruddy, K. J., & Hashmi, S. K. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000250 · Cited by 214
“DNA hypermethylation at CpG islands is induced in human cells after exposure to each of the following commonly used cancer chemotherapy agents: topoisomerase II inhibitors, antibiotics, microtubule inhibitors, DNA cross-linking agents, hydroxyurea, antimetabolites and methotrexate.73 Clinically relevant drugs reported…”
BackgroundCirculating miRNAs as Biomarkers for Neurodegenerative Disorders
Grasso, M., Piscopo, P., Confaloni, A., & Denti, M. (2014) · Molecules · doi:10.3390/molecules19056891 · Cited by 208
Zhang, W. C., Chin, T. M., Yang, H., Nga, M. E., Lunny, D. P., Lim, E. K. H., Sun, L. L., Pang, Y. H., Leow, Y. N., Malusay, S. R. Y., et al. (2016) · Nature Communications · doi:10.1038/ncomms11702 · Cited by 202
“Similarly, miR-23a and miR-130a were shown to be downregulated in chronic myeloid leukaemia 29 , and miR-29a/b/c was frequently reduced in a variety of cancers that include lung cancer 30 .”
The role of miR-29b in cancer: regulation, function, and signaling
Yang, J.-R., Yan, B., Guo, Q., Fu, F.-J., Wang, Z., Yin, Z., & Wei, Y.-B. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s75899 · Cited by 198
“that may revert aberrant DNA methylation by directly targeting both DNMT3A and DNMT3B.(23,64) In addition, it was demonstrated that miR-29b directly targets the 3′”
MicroRNA-29 family, a crucial therapeutic target for fibrosis diseases
He, Y., Huang, C., Lin, X., & Li, J. (2013) · Biochimie · doi:10.1016/j.biochi.2013.03.010 · Cited by 193
Pogribny, I. P., Starlard-Davenport, A., Tryndyak, V. P., Han, T., Ross, S. A., Rusyn, I., & Beland, F. A. (2010) · Laboratory Investigation · doi:10.1038/labinvest.2010.113 · Cited by 185
“The experimentally confirmed targets for miR-29 family are de novo DNA methyltransferases, namely, Dnmt3a and Dnmt3b.(28) Figure 3 shows that downregulation of miR-29c (Figure 3a) was associated with increased protein levels of Dnmt3a and Dnmt3b in the livers of C57BL/6J mice fed the methyl-deficient diet (Figure 3b)…”
Arif, K. M. T., Elliott, E. K., Haupt, L. M., & Griffiths, L. R. (2020) · Cancers · doi:10.3390/cancers12102922 · Cited by 183
“Non-small-cell lung cancer miR-29a miR-29b-3p miR-29c High DNMT-3a/DNMT-3b DNA Methylation FHIT/WWOX [62]”
BackgroundFabbri, M., Croce, C. M., & Calin, G. A. (2008) · The Cancer Journal · doi:10.1097/ppo.0b013e318164145e · Cited by 180
Self-citationZhou, Q., Costinean, S., Croce, C. M., Brasier, A. R., Merwat, S., Larson, S. A., Basra, S., & Verne, G. N. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.09.037 · Cited by 177
Self-citationTran, H. V., Piro, B., Reisberg, S., Tran, L. D., Duc, H. T., & Pham, M. C. (2013) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2013.05.007 · Cited by 176
“…target is added (miR-141, a prostate biomarker) a “signalon” response, i.e. a current increase, is observed while no current change occurs with noncomplementary miRNAs such as miR-103 (a colorectal cancer biomarker; Chen et al., 2012) or miR-29b-1 (a lung cancer biomarker; Fabbri et al., 2007).”
BackgroundTargeting MicroRNAs in Cancer Gene Therapy
Ji, W., Sun, B., & Su, C. (2017) · Genes · doi:10.3390/genes8010021 · Cited by 174
MicroRNAs, cancer and cancer stem cells
Zimmerman, A. L., & Wu, S. (2011) · Cancer Letters · doi:10.1016/j.canlet.2010.09.019 · Cited by 173
MicroRNA Delivery by Cationic Lipoplexes for Lung Cancer Therapy
Wu, Y., Crawford, M., Yu, B., Mao, Y., Nana-Sinkam, S. P., & Lee, L. J. (2011) · Molecular Pharmaceutics · doi:10.1021/mp2002076 · Cited by 172
Lung cancer in patients with idiopathic pulmonary fibrosis
Karampitsakos, T., Tzilas, V., Tringidou, R., Steiropoulos, P., Aidinis, V., Papiris, S. A., Bouros, D., & Tzouvelekis, A. (2017) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2017.03.016 · Cited by 171
“and as a therapeutic agent for lung cancer(112, 113).”
BackgroundMicroRNA-mediated drug resistance in breast cancer
Kutanzi, K. R., Yurchenko, O. V., Beland, F. A., Checkhun, V. F., & Pogribny, I. P. (2011) · Clinical Epigenetics · doi:10.1007/s13148-011-0040-8 · Cited by 170
“…of DNMT remain unclear, recent reports suggest a role of miR-29, miR-148, miR-152, and miR-194 in mediating DNMT expression (Duursma et al. 2008; Fabbri et al. 2007; Meng et al. 2010; Pan et al. 2010) in drug-resistant breast cancer cell lines (Kutanzi et al., unpublished data; Pogribny et al.…”
BackgroundEpigenetic aberrations during oncogenesis
Hatziapostolou, M., & Iliopoulos, D. (2011) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-010-0624-z · Cited by 169
MicroRNA in Glioblastoma: An Overview
Banelli, B., Forlani, A., Allemanni, G., Morabito, A., Pistillo, M. P., & Romani, M. (2017) · International Journal of Genomics · doi:10.1155/2017/7639084 · Cited by 168
Filigheddu, N., Gregnanin, I., Porporato, P. E., Surico, D., Perego, B., Galli, L., Patrignani, C., Graziani, A., & Surico, N. (2010) · Journal of Biomedicine and Biotechnology · doi:10.1155/2010/369549 · Cited by 162
“This network, converging on estrogen receptor 1 (ESR1), includes the DNA methyltransferases DNMT3A and DNMT3B that are validated targets of hsa-miR-29b and hsa-miR-29c, and of hsa-miR-29b, hsa-miR-29c, and hsamiR-148a, respectively [45, 46].”
BackgroundMicroRNAs: critical mediators of differentiation, development and disease
Friedman, J., & Jones, P. (2009) · Swiss Medical Weekly · doi:10.4414/smw.2009.12794 · Cited by 159
The roles of miRNAs as potential biomarkers in lung diseases
Alipoor, S. D., Adcock, I. M., Garssen, J., Mortaz, E., Varahram, M., Mirsaeidi, M., & Velayati, A. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.09.015 · Cited by 158
Labouesse, M. A., Dong, E., Grayson, D. R., Guidotti, A., & Meyer, U. (2015) · Epigenetics · doi:10.1080/15592294.2015.1114202 · Cited by 138
“Indeed, several in vitro studies have identified a number of candidate miRNAs capable of regulating the expression levels of DNMT1, DNMT3a, and DNMT3b mRNAs, respectively.(59,68) In particular, a recent study has demonstrated that DNMT3a expression can be reduced by mir-132, a miRNA that is also downregulated in the P…”
BackgroundInterplay between Epigenetics and Genetics in Cancer
Choi, J. D., & Lee, J.-S. (2013) · Genomics & Informatics · doi:10.5808/gi.2013.11.4.164 · Cited by 131
“Moreover, mutations of miRNAs, including miR-101 and miR-29, targeting epigenetically modifying enzymes, such as EZH2 [24, 25] and DNMT3 [26], respectively, are often found in human cancers.”
BackgroundFraczek, J., Bolleyn, J., Vanhaecke, T., Rogiers, V., & Vinken, M. (2013) · Archives of Toxicology · doi:10.1007/s00204-012-0983-3 · Cited by 119
miR-29c regulates BACE1 protein expression
Zong, Y., Wang, H., Dong, W., Quan, X., Zhu, H., Xu, Y., Huang, L., Ma, C., & Qin, C. (2011) · Brain Research · doi:10.1016/j.brainres.2011.04.035 · Cited by 117
Desaulniers, D., Xiao, G.-H., Lian, H., Feng, Y.-L., Zhu, J., Nakai, J., & Bowers, W. J. (2009) · International Journal of Toxicology · doi:10.1177/1091581809337918 · Cited by 114
“Explaining the origin of these chemical-specific imbalances in DNMT mRNA expression would require the investigation of end points known to be relevant to the DNMT promoters, including occupation of dioxin response elements, the methylation of CpG dinucleotides, and the role of Sp regulatory sites,(55,56) as well as mi…”
BackgroundGamper, C. J., Agoston, A. T., Nelson, W. G., & Powell, J. D. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802960 · Cited by 100
The role of miRNA in the direct and indirect effects of ionizing radiation
Dickey, J. S., Zemp, F. J., Martin, O. A., & Kovalchuk, O. (2011) · Radiation and Environmental Biophysics · doi:10.1007/s00411-011-0386-5 · Cited by 88
Mavragani, C. P., Nezos, A., Sagalovskiy, I., Seshan, S., Kirou, K. A., & Crow, M. K. (2018) · Journal of Autoimmunity · doi:10.1016/j.jaut.2017.10.004 · Cited by 85
Du, L., Schageman, J. J., Irnov, Girard, L., Hammond, S. M., Minna, J. D., Gazdar, A. F., & Pertsemlidis, A. (2010) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-29-75 · Cited by 73
“Expression levels of miR-29a, miR29b, and miR-29c were previously shown to be inversely correlated with levels of DNA methyltransferase (DNMT) -3A and -3B [14], two key enzymes involved in DNA methylation that have been shown to promote tumorigenesis [63].”
BackgroundEpigenetic genes and epilepsy — emerging mechanisms and clinical applications
Van Loo, K. M. J., Carvill, G. L., Becker, A. J., Conboy, K., Goldman, A. M., Kobow, K., Lopes-Cendes, I., Reid, C. A., van Vliet, E. A., & Henshall, D. C. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00693-y · Cited by 68
Markers of cellular senescence.
Carnero, A. (2013) · Methods in Molecular Biology · doi:10.1007/978-1-62703-239-1_4 · Cited by 68
Interplay between the miRNome and the epigenetic machinery: Implications in health and disease
Poddar, S., Kesharwani, D., & Datta, M. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.25819 · Cited by 57
MicroRNA in Brain pathology: Neurodegeneration the Other Side of the Brain Cancer
Godlewski, J., Lenart, J., & Salinska, E. (2019) · Non-Coding RNA · doi:10.3390/ncrna5010020 · Cited by 52
Nolan, K., Walter, F., Tuffy, L. P., Poeschel, S., Gallagher, R., Haunsberger, S., Bray, I., Stallings, R. L., Concannon, C. G., & Prehn, J. H. M. (2016) · European Journal of Neuroscience · doi:10.1111/ejn.13160 · Cited by 40
“miR-29a has been shown to have multiple targets across a range of non-neuronal systems (Fabbri et al., 2007).”
BackgroundBoddicker, R. L., Koltes, J. E., Fritz‐Waters, E. R., Koesterke, L., Weeks, N., Yin, T., Mani, V., Nettleton, D., Reecy, J. M., Baumgard, L. H., et al. (2016) · Animal Genetics · doi:10.1111/age.12468 · Cited by 36
Micromanaging aging with miRNAs: new messages from the nuclear envelope
Ugalde, A. P., Español, Y., & López-Otín, C. (2011) · Nucleus · doi:10.4161/nucl.2.6.17986 · Cited by 34
Lin, M., Chen, Y., Lee, M., Weng, K., Chang, H., Yu, S., Dong, B., Kuo, F., Hung, L., Liu, L., et al. (2018) · Oncology Letters · doi:10.3892/ol.2018.8557 · Cited by 30
“Numerous dysregulated miRNAs have been reported in lung cancer cells, including let-7 and miR-17, -20a, -29, -107, -126, -138, and -185 (11-17).”
BackgroundFan, X., Tao, S., Li, Q., Deng, B., Tan, Q.-Y., & Jin, H. (2022) · Molecular Therapy - Oncolytics · doi:10.1016/j.omto.2021.12.014 · Cited by 26
O’Tuathaigh, C. M. P., Fumagalli, F., Desbonnet, L., Perez-Branguli, F., Moloney, G., Loftus, S., O’Leary, C., Petit, E., Cox, R., Tighe, O., et al. (2017) · Schizophrenia Bulletin · doi:10.1093/schbul/sbw120 · Cited by 22
Genome-wide methylated CpG island profiles of melanoma cells reveal a melanoma coregulation network
Li, J.-L., Mazar, J., Zhong, C., Faulkner, G. J., Govindarajan, S. S., Zhang, Z., Dinger, M. E., Meredith, G., Adams, C., Zhang, S., et al. (2013) · Scientific Reports · doi:10.1038/srep02962 · Cited by 21
(2012) · Digital Access to Scholarship at Harvard (DASH) (Harvard University)
Metadata
- Authors
- Fabbri, M., Garzon, R., Cimmino, A., Liu, Z., Zanesi, N., Callegari, E., Liu, S., Alder, H., Costinean, S., Fernandez-Cymering, C., Volinia, S., Guler, G., Morrison, C. D., Chan, K. K., Marcucci, G., Calin, G. A., Huebner, K., & Croce, C. M.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2007-10-02
- Volume
- 104
- Issue
- 40
- Pages
- 15805-15810
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2103177465
- Cited by
- 1,673
- References
- 34
- FWCI
- 27.00
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.